Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.

Also called NCT04654988

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04654988
  • EudraCT 2020-003877-23
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04654988. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-01 (actual); primary completion 2027-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.
Acronym
IMPROVE-MC
Condition
Myocarditis
Condition
Heart Failure
Condition
Endomyocardial Biopsy
Condition
Cardiomyopathies, Secondary
Condition
Immunosuppression
Intervention (Drug)
Prednisone
Intervention (Drug)
Azathioprine
Intervention (Drug)
Placebo Prednisone
Intervention (Drug)
Placebo Azathioprine
Lead sponsor
Medical University of Warsaw (class: other)

Record details

Record id
cardio:ct-nct04654988
Content hash
6c22fff3926df25ee91c18375630134fe20c08398fb05204f13266e24219c356